Raymond James Financial Inc. Takes $42.78 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Raymond James Financial Inc. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 231,720 shares of the medical research company's stock, valued at approximately $42,776,000. Raymond James Financial Inc. owned 0.45% of Charles River Laboratories International as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock worth $1,136,938,000 after purchasing an additional 60,497 shares during the period. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after buying an additional 335,658 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Geode Capital Management LLC boosted its stake in Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after acquiring an additional 14,787 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Charles River Laboratories International by 17.1% in the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock valued at $190,910,000 after purchasing an additional 151,159 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on CRL. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Mizuho dropped their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. UBS Group restated a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Stock Down 3.3 %

Shares of NYSE:CRL traded down $3.47 during midday trading on Monday, hitting $102.59. The stock had a trading volume of 221,707 shares, compared to its average volume of 891,401. The company has a market cap of $5.04 billion, a P/E ratio of 684.11, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The business's 50-day simple moving average is $151.07 and its 200-day simple moving average is $173.76. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the firm posted $2.46 EPS. The company's quarterly revenue was down 1.1% on a year-over-year basis. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).